Acepodia is seeking collaborators who are interested in developing the next generation of cellular immunotherapies for cancer and other diseases with unmet medical needs. Acepodia believes the ACC technology can significantly advance the field of cellular therapeutics by directing allogeneic oNK and other effector cells directly to tumors. Our commitment is to deliver effective and affordable treatments for patients. Please contact us if you share this vision.
We have collaborated with biopharmaceutical partners and academic institutes worldwide. For further discussion on partnership with Acepodia, please contact: